Related Experiment Video
Updated: Jan 23, 2026
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
CD93 is Selectively Expressed on Human Myeloma Cells but Not on B Lymphocytes
Shohreh Fakhari1, Hamed Bashiri, Bayazid Ghaderi
1Cancer and Immunology Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Insights
CD93 is significantly elevated on multiple myeloma cells compared to normal B cells. This finding suggests CD93 may play a crucial role in multiple myeloma development.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- CD93, a C1q receptor, is expressed on various immune cells including hematopoietic stem cells and B cell progenitors.
- Previous research indicates CD93's role in plasma cell development, with CD93-deficient mice showing impaired plasma cell maturation.
Purpose of the Study:
- To investigate the expression levels of CD93 on multiple myeloma (MM) cells.
- To determine if CD93 expression differs between MM cells and normal B cells.
Main Methods:
- Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) and Fluorescence Activated Cell Sorting (FACS) were used to analyze CD93 expression.
- CD93 expression was examined on cultured human MM and B cell lines.
- Primary CD19+ B cells and CD19-/CD138+ MM cells were isolated using MACS columns for further analysis.
Main Results:
- CD93 mRNA levels were significantly higher in MM cell lines compared to B cell lines.
- MM cell lines exhibited higher surface protein levels of CD93 than B cell lines.
- Primary MM cells (CD19-/CD138+) showed significantly higher CD93 expression than primary B cells (CD19+).
Conclusions:
- CD93 is demonstrably expressed on multiple myeloma cells.
- CD93 may play a significant role in the pathogenesis of multiple myeloma.
- Further research is warranted to elucidate the specific role of CD93 in MM.
Background:
CD93 has originally been known as a C1q receptor, and many studies have demonstrated that CD93 is expressed on hematopoietic stem cells, B cell progenitors, myeloid and monocytic cells. Moreover, CD93 is shown to be expressed on long-lived plasma cells, and CD93 deficient-mice display an impairment in plasma cell development.
Objective:
To investigate the expression of CD93 on multiple myeloma (MM) cells.
Methods:
Human MM and B cell lines were cultured, and the expression of CD93 was examined on these cells by quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) and Fluorescence Activated Cell Sorting (FACS). In addition, CD19+ primary B cells and CD19-/CD138+ primary MM cells were isolated by MACS columns, and CD93 expression was further analyzed on these cells.
Results:
qRT-PCR data showed that CD93 expression at mRNA level was much higher in MM cell lines compared with B cell lines. In addition, MM cell lines expressed a higher amount of surface CD93 at protein level compared with B cell lines. More importantly, CD93 expression was significantly higher in CD19-/CD138+ primary MM cells than in CD19+ primary B cells isolated from the bone marrow of patients with MM.
Conclusion:
We demonstrated that CD93 is expressed on myeloma cells and, that CD93 could play a key role in the pathogenesis of MM. Further studies are necessary to explore this possible role.
Related Concept Videos
01:58Cell Specific Gene Expression
01:58Cell Specific Gene Expression
02:35Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
00:57Antibiotic Selection
01:32What is Natural Selection?